Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause

Archer, David F.; Pinkerton, JoAnn V.; Guico-Pabia, Christine J.; Hwang, Eunhee; Cheng, Ru-fong J.; Investigators, Study

doi:10.1097/gme.0b013e3182775fe9

Cited by 17 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several non-hormonal compounds including clonidine, gabapentin, and some of serotonin and serotonin-norepinephrine reuptake inhibitors have been used for relief of VMS. Desvenlafaxine, a novel serotonin norepinephrine reuptake inhibitor, has been shown to be effective for the treatment of moderate to severe hot flashes associated with menopause [11,12,13,14,15,16,17,18]; however, the results have not been entirely consistent [19]. There have been potential cardiovascular risks associated with the use of desvenlafaxine in this patient population [11].…”

Section: Introductionmentioning

confidence: 81%

“…Six trials [12,13,17,18,19,25 ]describing administration of desvenlafaxine 100 mg to patients included data on adverse events. The adverse effects included nausea, constipation, diarrhea, dry mouth, hypertension, somnolence, asthenia dizziness, insomnia, etc.…”

Section: Resultsmentioning

confidence: 99%

“…Most of these events were moderate in severity and had a short duration. There is no evidence for an increased risk of cardiovascular, cerebrovascular, or hepatic events associated with desvenlafaxine 100 mg/day compared with placebo for the treatment of menopausal VMS within 1 year [18]. A recent published well-written review also concluded that desvenlafaxine at doses of 100 mg have not been shown to cause significant side effects [28].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and Safety of Desvenlafaxine Treatment for Hot Flashes Associated with Menopause: A Meta-Analysis of Randomized Controlled Trials

Sun

Yanqing

Zhang³

2013

Gynecol Obstet Invest

View full text Add to dashboard Cite

Vasomotor symptoms, such as daytime hot flashes and nighttime awakenings due to hot flashes, are commonly associated with menopausal women. The aim of this study was to assess desvenlafaxine in moderate to severe hot flashes in postmenopausal women. Electronic databases were searched for relevant randomized controlled trials that compared desvenlafaxine to placebo for postmenopausal women affected with hot flashes. The main outcomes were mean differences (MD) or standardized mean differences (SMD) and 95% confidence interval (CI) for change of the hot flashes. Six randomized controlled trials were identified in the meta-analysis. Pooled change of moderate and severe hot flashes frequency reduced SMD of -0.49 (95% CI -0.91 to -0.07) in desvenlafaxine 100 mg and -0.36 (95% CI -0.54 to -0.19) in desvenlafaxine 150 mg at week 12. Desvenlafaxine 100 mg reduced moderate and severe hot flashes frequency SMD of -0.74 (95% CI -1.05 to -0.44) within 26 weeks. There is no evidence for an increased risk of cardiovascular, cerebrovascular, or hepatic events associated with desvenlafaxine 100 mg/day. The meta-analysis suggests that treatment with desvenlafaxine 100 mg/day is associated with a significant reduction of moderate to severe hot flashes in postmenopausal women. Desvenlafaxine appears both safe and effective for treating hot flushes for up to 12 months.

show abstract

Section: Introductionmentioning

confidence: 81%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Desvenlafaxine Treatment for Hot Flashes Associated with Menopause: A Meta-Analysis of Randomized Controlled Trials

Sun

Yanqing

Zhang³

2013

Gynecol Obstet Invest

View full text Add to dashboard Cite

show abstract

“…27 Archer and David et al suggests that no evidence for an increased risk of cardiovascular, cerebrovascular, or hepatic events associated with desvenlafaxine 100mg/day compared with placebo for the treatment of menopausal vasomotor symptoms. 28 Limitations of the study was found to be our study is limited by its small sample size and there is lack of uniformity among the individuals in the given cohort because they were on different lifestyles for the disease processes related to our study and which can alter the serum leptin, TNF-α and lipid profile which are the variables of interest. The distribution of sex is not even in the given cohort with female population predominate than the male population.…”

Section: Lipid Profile In Correlation To Weight Neutral Antidepressantsmentioning

confidence: 99%

The relationship of serum leptin, serum TNF-α, plasma lipids and obesity parameters in patients treated with weight neutral antidepressants

et al. 2018

View full text Add to dashboard Cite

Background: Leptin and tumor necrosis factor (TNFα) are involved in weight regulation1. Elevated lipids are frequently encountered in obese people which are helpful in the formation of atherosclerotic plaques in the coronary arteries. This study helps us to know whether weight neutral antidepressant therapy can be therapeutic option in those with obesity associated with depression.Methods: It is a Longitudinal study of sample size 72 where Patients with obesity attending to JSS hospital who are found to be depressive in both inpatients and out patients fulfilling the inclusion and exclusion criteria.Results: Our study showed mean difference value of weight, BMI and waist circumference, S. leptin, S.TNF-α, S. total cholesterol, S. LDL-C, S. VLDL-C, triglycerides of obese patients treated with lifestyle modifications, psychotherapy and weight neutral antidepressants at baseline and 3rd month was significantly decreased when compared to obese patients treated with lifestyle modifications, psychotherapy alone at baseline and 3rd month is 3.5kgs, 1.2kg/m2, 0.89cm, 9.53pg/ml, 10.86pg/ml, 22.34mg/dl, 17.94mg/dl, 4.42mg/dl, 21.78mg/dl and 1.2kgs, 0.32kg/m2, 0.02cm, 5.22pg/ml, 7.86pg/ml, 11.72mg/dl, 15.37mg/dl, 1.98mg/dl, 9.54mg/dl respectively (p=0.0001).Conclusions: Our study demonstrated a significant weight loss, and significant decrease in S. Leptin, S. TNF- α, TC, LDL-C, VLDL-C, triglycerides, when obese patients treated with lifestyle modifications, psychotherapy and weight neutral antidepressant (Desvenlafaxine).

show abstract

“…The goals of rehabilitation are to help survivors become as independent as possible and to attain the best possible quality of life. Even though rehabilitation does not «cure» the effects of stroke in that it does not reverse brain damage, rehabilitation can substantially help people achieve the best possible long-term outcome [1,6].…”

mentioning

confidence: 99%

Investigation of clinical and psychological peculiarities of patients at early stages of hypertensive encephalopathy

Sergeevna¹,

Mikhailovich²,

Stepanovich³

et al. 2017

Medical news of the North Caucasus

View full text Add to dashboard Cite

Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year in women with vasomotor symptoms associated with menopause

Abstract: There is no evidence for an increased risk of cardiovascular, cerebrovascular, or hepatic events associated with desvenlafaxine 100 mg/day compared with placebo for the treatment of menopausal vasomotor symptoms.

Cited by 17 publications

References 23 publications

Efficacy and Safety of Desvenlafaxine Treatment for Hot Flashes Associated with Menopause: A Meta-Analysis of Randomized Controlled Trials

Efficacy and Safety of Desvenlafaxine Treatment for Hot Flashes Associated with Menopause: A Meta-Analysis of Randomized Controlled Trials

The relationship of serum leptin, serum TNF-α, plasma lipids and obesity parameters in patients treated with weight neutral antidepressants

Investigation of clinical and psychological peculiarities of patients at early stages of hypertensive encephalopathy

Contact Info

Product

Resources

About